Metabolomics in Schizophrenia and Major Depressive Disorder

Frontiers in Biology

Volumn 11, Issue 3, 2016, Pages 222-231

  Petrovchich, Iva ^b   Sosinsky, Alexandra ^a   Konde, Anish ^c   Archibald, Abigail ^a   Henderson, David ^d   Maletic Savatic, Mirjana ^e   Milanovic, Snezana ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF LOUISIANA AT LAFAYETTE   (United States)

^d BOSTON MEDICAL CENTER   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Major Depressive Disorder; metabolomics; omics; Schizophrenia; systems biology

Indexed keywords

EID: 84978971663     PISSN: 16747984     EISSN: 16747992     Source Type: Journal    
DOI: 10.1007/s11515-016-1400-8     Document Type: Review

References (108)

1. Abrusán G (2012). Somatic transposition in the brain has the potential to influence the biosynthesis of metabolites involved in Parkinson’s disease and schizophrenia. Biol Direct, 7 (1): 41
2. Alkondon M, Pereira E F, Yu P, Arruda E Z, Almeida L E, Guidetti P, Fawcett W P, Sapko M T, Randall W R, Schwarcz R, Tagle D A, Albuquerque E X (2004). Targeted deletion of the kynurenine aminotransferase ii gene reveals a critical role of endogenous kynurenic acid in the regulation of synaptic transmission via a7 nicotinic receptors in the hippocampus. J Neurosci, 24(19): 4635–4648
3. Allen G I, Maletic-Savatic M (2011). Sparse non-negative generalized PCA with applications to metabolomics. Bioinformatics, 27 (21): 3029–3035
4. Andreou D, Söderman E, Axelsson T, Sedvall G C, Terenius L, Agartz I, Jönsson E G (2014). Polymorphisms in genes implicated in dopamine, serotonin and noradrenalin metabolism suggest association with cerebrospinal fluid monoamine metabolite concentrations in psychosis. Behav Brain Funct, 10 (1): 26
5. Appleton K M, Rogers P J, Ness A R (2008). Is there a role for n-3 longchain polyunsaturated fatty acids in the regulation of mood and behaviour? A review of the evidence to date from epidemiological studies, clinical studies and intervention trials. Nutr Res Rev, 21(1): 13–41
6. Arai M, Yuzawa H, Nohara I, Ohnishi T, Obata N, Iwayama Y, Haga S, Toyota T, Ujike H, Arai M, Ichikawa T, Nishida A, Tanaka Y, Furukawa A, Aikawa Y, Kuroda O, Niizato K, Izawa R, Nakamura K, Mori N, Matsuzawa D, Hashimoto K, Iyo M, Sora I, Matsushita M, Okazaki Y, Yoshikawa T, Miyata T, ItokawaM(2010). Enhanced carbonyl stress in a subpopulation of schizophrenia. Arch Gen Psychiatry, 67(6): 589–597
7. Arnold J M, Choi W T, Sreekumar A, Maletic-Savatic M (2015). Analytical strategies for studying stem cell metabolism, Front Biol, 10 (2): 141–153
8. Asberg M, Bertilsson L, Mårtensson B, Scalia-Tomba G P, Thorén P, Träskman-Bendz L (1984). CSF monoamine metabolites in melancholia. ActaPsychiatrScand, 69(3): 201–219
9. Ashcroft GW, Crawford T B, Eccleston D, Sharman D F, MacDougall E J, Stanton J B, Binns J K (1966). 5-hydroxyindole compounds in the cerebrospinal fluid of patients with psychiatric or neurological diseases. Lancet, 2(7472): 1049–1052
10. Bernstein H G, Bogerts B, Keilhoff G (2005). The many faces of nitric oxide in schizophrenia. A review. Schizophr Res, 78(1): 69–86
11. Bitanihirwe B K, Woo T U (2011). Oxidative stress in schizophrenia: an integrated approach. NeurosciBiobehav Rev, 35(3): 878–893
12. Botas A, Campbell H M, Han X, Maletic-Savati M (2015). Metabolomics of neurodegenerative diseases, Int Rev Neurobiol, 122: 53–80
13. Bowers M B (1973). 5-Hydroxyindoleacetic acid (5HIAA) and homovanillic acid (HVA) following probenecid in acute psychotic patients treated with phenothiazines. Psychopharmacologia, 28(4): 309–318
14. Bundo M, Toyoshima M, Okada Y, Akamatsu W, Ueda J, Nemoto-Miyauchi T, Sunaga F, Toritsuka M, Ikawa D, Kakita A, Kato M, Kasai K, Kishimoto T, Nawa H, Okano H, Yoshikawa T, Kato T, Iwamoto K (2014). Increased l1 retrotransposition in the neuronal genome in schizophrenia. Neuron, 81(2): 306–313
15. Cantoni G L, Mudd S H, Andreoli V (1989). Affective disorders and Sadenosylmethionine: a new hypothesis. Trends Neurosci, 12(9): 319–324
16. Capuron L, Neurauter G, Musselman D L, Lawson D H, Nemeroff C B, Fuchs D, Miller A H (2003). Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol Psychiatry, 54(9): 906–914
17. Cherlyn S Y, Woon P S, Liu J J, Ong W Y, Tsai G C, Sim K (2010). Genetic association studies of glutamate, GABA and related genes in schizophrenia and bipolar disorder: a decade of advance. Neurosci Biobehav Rev, 34(6): 958–977
18. Chumakov I, Blumenfeld M, Guerassimenko O, Cavarec L, Palicio M, Abderrahim H, Bougueleret L, Barry C, Tanaka H, La Rosa P, Puech A, Tahri N, Cohen-Akenine A, Delabrosse S, Lissarrague S, Picard F P, Maurice K, Essioux L, Millasseau P, Grel P, Debailleul V, Simon A M, Caterina D, Dufaure I, Malekzadeh K, Belova M, Luan J J, Bouillot M, Sambucy J L, Primas G, Saumier M, Boubkiri N, Martin-Saumier S, Nasroune M, Peixoto H, Delaye A, Pinchot V, Bastucci M, Guillou S, Chevillon M, Sainz-Fuertes R, Meguenni S, Aurich-Costa J, Cherif D, Gimalac A, van Duijn C, Gauvreau D, Ouellette G, Fortier I, Raelson J, Sherbatich T, Riazanskaia N, Rogaev E, Raeymaekers P, Aerssens J, Konings F, Luyten W, Macciardi F, Sham P C, Straub R E, Weinberger D R, Cohen N, Cohen D (2002). Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci U S A, 99(21): 13675–13680
19. Craft S, Watson G S (2004). Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol, 3(3): 169–178
20. Domino E F, Krause R R (1974). Free and bound serum tryptophan in drug-free normal controls and chronic schizophrenic patients. Biol Psychiatry, 8(3): 265–279
21. Erhardt S, Blennow K, Nordin C, Skogh E, Lindström L H, Engberg G (2001). Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett, 313(1-2): 96–98
22. Evrony G D, Lee E, Mehta B K, Benjamini Y, Johnson R M, Cai X, Yang L, Haseley P, Lehmann H S, Park P J, Walsh C A (2015). Cell lineage analysis in human brain using endogenous retroelements. Neuron, 85(1): 49–59
23. Ferentinos P, Dikeos D (2012). Genetic correlates of medical comorbidity associated with schizophrenia and treatment with antipsychotics. Curr Opin Psychiatry, 25(5): 381–390
24. Fernández-Novoa L, Cacabelos R (2001). Histamine function in brain disorders. Behav Brain Res, 124(2): 213–233
25. Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Utsunomiya M, Nakatani M, Sadamoto K, Yoshio T (2014). Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One, 9 (7): e101652
26. Garelis E, Gillin J C, Wyatt R J, Neff N (1975). Elevated blood serotonin concentration in unmedicated chronic schizophrenic patients. Am J Psychiatry, 132(2): 184–186
27. Gattaz W F, Brunner J, Schmitt A, Maras A (1994). Accelerated breakdown of membrane phospholipids in schizophrenia—implications for the hypofrontality hypothesis. Fortschr Neurol Psychiatr, 62 (12): 489–496
28. Gattaz W F, Hübner C V, Nevalainen T J, Thuren T, Kinnunen P K (1990). Increased serum phospholipase A2 activity in schizophrenia: a replication study. Biol Psychiatry, 28(6): 495–501
29. Gattaz WF, Köllisch M, Thuren T, Virtanen J A, Kinnunen P K J (1987). Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy. Biol Psychiatry, 22 (4): 421–426
30. Gillin J C, Kaplan J A, Wyatt R J (1976). Clinical effects of tryptophan in chronic schizophrenic patients. Biol Psychiatry, 11(5): 635–639
31. Glinsky G V (2015). Transposable elements and DNA methylation create in embryonic stem cells human-specific regulatory sequences associated with distal enhancers and noncoding RNAs. Genome Biol Evol, 7(6): 1432–1454
32. Gysin R, Kraftsik R, Sandell J, Bovet P, Chappuis C, Conus P, Deppen P, Preisig M, Ruiz V, Steullet P, Tosic M, Werge T, Cuénod M, Do K Q (2007). Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc Natl Acad Sci U S A, 104(42): 16621–16626
33. Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M (2003). Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry, 60(6): 572–576
34. Hashimoto K, Shimizu E, Iyo M (2005). Dysfunction of glia-neuron communication in pathophysiology of schizophrenia. Curr Psychiatry Rev, 1(2): 151–163
35. He Y, Yu Z, Giegling I, Xie L, Hartmann A M, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D (2012). Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry, 2 (8): e149
36. Hernández-Benítez R, Vangipuram S D, Ramos-Mandujano G, Lyman W D, Pasantes-Morales H (2013). Taurine enhances the growth of neural precursors derived from fetal human brain and promotes neuronal specification. Dev Neurosci, 35(1): 40–49
37. Hilmas C, Pereira E F, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque E X (2001). The brain metabolite kynurenic acid inhibits a7 nicotinic receptor activity and increases non-a7 nicotinic receptor expression: physiopathological implications. J Neurosci, 21 (19): 7463–7473
38. Hosak L (2013). New findings in the genetics of schizophrenia. World J Psychiatry, 3(3): 57–61
39. Inoue K, Okamoto M, Shibato J, Lee M C, Matsui T, Rakwal R, Soya H (2015). Long-term mild, rather than intense, exercise enhances adult hippocampal neurogenesis and greatly changes the transcriptomic profile of the hippocampus. PLoS One, 10 (6): e0128720
40. Iwayama Y, Hattori E, Maekawa M, Yamada K, Toyota T, Ohnishi T, Iwata Y, Tsuchiya K J, Sugihara G, Kikuchi M, Hashimoto K, Iyo M, Inada T, Kunugi H, Ozaki N, Iwata N, Nanko S, Iwamoto K, Okazaki Y, Kato T, Yoshikawa T (2010). Association analyses between brainexpressed fatty-acid binding protein (FABP) genes and schizophrenia and bipolar disorder. Am J Med Genet B Neuropsychiatr Genet, 153B(2): 484–493
41. Jackman H, Luchins D, Meltzer H Y (1983). Platelet serotonin levels in schizophrenia: relationship to race and psychopathology. Biol Psychiatry, 18(8): 887–902
42. Joseph M H, Owen F, Baker H F, Bourne R C (1977). Platelet serotonin concentration and monoamine oxidase activity in unmedicated chronic schizophrenic and in schizoaffective patients. Psychol Med, 7(1): 159–162
43. Kaddurah-Daouk R, Yuan P, Boyle S H, Matson W, Wang Z, Zeng Z B, Zhu H, Dougherty G G, Yao J K, Chen G, Guitart X, Carlson P J, Neumeister A, Zarate C, Krishnan R R, Manji H K, Drevets W (2012). Cerebrospinal fluid metabolome in mood disorders-remission state has a unique metabolic profile. Sci Rep, 2 (667): 667
44. Kempf L, Nicodemus K K, Kolachana B, Vakkalanka R, Verchinski B A, Egan M F, Straub R E, Mattay V A, Callicott J H, Weinberger D R, Meyer-Lindenberg A (2008). Functional polymorphisms in PRODH are associated with risk and protection for schizophrenia and frontostriatal structure and function. PLoS Genet, 4 (11): e1000252
45. Kolakowska T, Molyneux S G (1987). Platelet serotonin concentration in schizophrenic patients. Am J Psychiatry, 144(2): 232–234
46. Kotronen A, Velagapudi V R, Yetukuri L, Westerbacka J, Bergholm R, Ekroos K, Makkonen J, Taskinen M R, Oresic M, Yki-Järvinen H (2009). Serum saturated fatty acids containing triacylglycerols are better markers of insulin resistance than total serum triacylglycerol concentrations. Diabetologia, 52(4): 684–690
47. Kotronen A, Yki-Järvinen H (2008). Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol, 28(1): 27–38
48. Lee L H, Shui G, Farooqui A A, Wenk M R, Tan C H, Ong W Y (2009). Lipidomic analyses of the mouse brain after antidepressant treatment: evidence for endogenous release of long-chain fatty acids? Int J Neuropsychopharmacol, 12(7): 953–964
49. Liu H, Heath S C, Sobin C, Roos J L, Galke B L, Blundell M L, Lenane M, Robertson B, Wijsman E M, Rapoport J L, Gogos J A, Karayiorgou M (2002). Genetic variation at the 22q11 PRODH2/ DGCR6 locus presents an unusual pattern and increases susceptibility to schizophrenia. Proc Natl Acad Sci U S A, 99(6): 3717–3722
50. Liu X, Zheng P, Zhao X, Zhang Y, Hu C, Li J, Zhao J, Zhou J, Xie P, Xu G (2015). Discovery and validation of plasma biomarkers for major depressive disorder classification based on liquid chromatographymass spectrometry. J Proteome Res, 14(5): 2322–2330
51. Luykx J J, Bakker S C, Lentjes E, Neeleman M, Strengman E, Mentink L, De Young J, de Jong S, Sul J H, Eskin E, van Eijk K, van Setten J, Buizer-Voskamp J E, Cantor R M, Lu A, van Amerongen M, van Dongen E P, Keijzers P, Kappen T, Borgdorff P, Bruins P, Derks E M, Kahn R S, Ophoff R A (2014). Genome-wide association study of monoamine metabolite levels in human cerebrospinal fluid. Mol Psychiatry, 19(2): 228–234
52. Madeira C, Freitas M E, Vargas-Lopes C, Wolosker H, Panizzutti R (2008). Increased brain D-amino acid oxidase (DAAO) activity in schizophrenia. Schizophr Res, 101(1-3): 76–83
53. Maekawa M, Owada Y, Yoshikawa T (2011). Role of polyunsaturated fatty acids and fatty acid binding protein in the pathogenesis of schizophrenia. Curr Pharm Des, 17(2): 168–175
54. Maletic-Savatic M, Vingara L K, Manganas L N, Li Y, Zhang S, Sierra A, Hazel R, Smith D, Wagshul M E, Henn F, Krupp L, Enikolopov G, Benveniste H, Djuric P M, Pelczer I (2008). Metabolomics of neural progenitor cells: a novel approach to biomarker discovery. Cold Spring Harb Symp Quant Biol, 73:389–401
55. Manowitz P, Gilmour D G, Racevskis J (1973). Low plasma tryptophan levels in recently hospitalized schizophrenics. Biol Psychiatry, 6(2): 109–118
56. Martins-de-Souza D (2014). Proteomics, metabolomics, and protein interactomics in the characterization of the molecular features of major depressive disorder. Dialogues Clin Neurosci, 16(1): 63–73
57. Middleton F A, Mirnics K, Pierri J N, Lewis D A, Levitt P (2002). Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J Neurosci, 22(7): 2718–2729
58. Milanovic S M, Thermenos H W, Goldstein J M, Brown A, Gabrieli S W, Makris N, Tsuang M T, Buka S L, Seidman L J (2011). Medial prefrontal cortical activation during working memory differentiates schizophrenia and bipolar psychotic patients: a pilot fMRI study. Schizophr Res, 129(2-3): 208–210
59. Moon M L, Joesting J J, Lawson M A, Chiu G S, Blevins N A, Kwakwa K A, Freund G G (2014). The saturated fatty acid, palmitic acid, induces anxiety-like behavior in mice. Metabolism, 63(9): 1131–1140
60. Moreno F A, Parkinson D, Palmer C, Castro W L, Misiaszek J, El Khoury A, Mathé A A, Wright R, Delgado P L (2010). CSF neurochemicals during tryptophan depletion in individuals with remitted depression and healthy controls. Eur Neuropsychopharmacol, 20(1): 18–24
61. Mück-Seler D, Jakovljevic M, Deanovic Z (1988). Time course of schizophrenia and platelet 5-HT level. Biol Psychiatry, 23(3): 243–251
62. Nichenametla S N, Ellison I, Calcagnotto A, Lazarus P, Muscat J E, Richie J P (2008). Functional significance of the GAG trinucleotide-repeat polymorphism in the gene for the catalytic subunit of gamma-glutamylcysteine ligase. Free Radic Biol Med, 45 (5): 645–650
63. Nunes A F, Amaral J D, Lo A C, Fonseca M B, Viana R J, Callaerts-Vegh Z, D’Hooge R, Rodrigues C M (2012). TUDCA, a bile acid, attenuates amyloid precursor protein proceßsing and amyloid-ß deposition in APP/PS1 mice. Mol Neurobiol, 45(3): 440–454
64. Olney J W, Farber N B (1995). Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry, 52(12): 998–1007
65. Orešic M, Tang J, Seppänen-Laakso T, Mattila I, Saarni S E, Saarni S I, Lönnqvist J, Sysi-Aho M, Hyötyläinen T, Perälä J, Suvisaari J (2011). Metabolome in schizophrenia and other psychotic disorders: a general population-based study. Genome Med, 3 (3): 19
66. Paoletti L, Elena C, Domizi P, Banchio C (2011). Role of phosphatidylcholine during neuronal differentiation. IUBMB Life, 63(9): 714–720
67. Park H R, Kim J Y, Park K Y, Lee J (2011). Lipotoxicity of palmitic Acid on neural progenitor cells and hippocampal neurogenesis. Toxicol Res, 27(2): 103–110
68. Payne I R, Walsh E M, Whittenburg E J (1974). Relationship of dietary tryptophan and niacin to tryptophan metabolism in schizophrenics and nonschizophrenics. Am J Clin Nutr, 27(6): 565–571
69. Peterson C, Vannucci M, Karakas C, Choi W, Ma L, Maletic-Savatic M (2013). Inferring metabolic networks using the Bayesian adaptive graphical lasso with informative priors. Stat Interface, 6(4): 547–558
70. Prell G D, Green J P, Kaufmann C A, Khandelwal J K, Morrishow A M, Kirch D G, Linnoila M, Wyatt R J (1995). Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res, 14(2): 93–104
71. Raffa M, Mechri A, Othman L B, Fendri C, Gaha L, Kerkeni A (2009). Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry, 33(7): 1178–1183
72. Ramos-Loyo J, Medina-Hernández V, Estarrón-Espinosa M, Canales-Aguirre A, Gómez-Pinedo U, Cerdán-Sánchez L F (2013). Sex differences in lipid peroxidation and fatty acid levels in recent onset schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry, 44: 154–161
73. Reiter R J, Tan D X, Jou M J, Korkmaz A, Manchester L C, Paredes S D (2008). Biogenic amines in the reduction of oxidative stress: melatonin and its metabolites. Neuro Endocrinol Lett, 29(4): 391–398
74. Santin L J, Bilbao A, Pedraza C, Matas-Rico E, López-Barroso D, Castilla-Ortega E, Sánchez-López J, Riquelme R, Varela-Nieto I, de la Villa P, Suardíaz M, Chun J, de Fonseca F R, Estivill-Torrús G (2009). Behavioral phenotype of maLPA1-null mice: increased anxiety-like behavior and spatial memory deficits. Genes Brain Behav, 8(8): 772–784
75. Santos-Soto I J, Chorna N, Carballeira N M, Vélez-Bartolomei J G, Méndez-Merced A T, Chornyy A P, Peña de Ortiz S (2013). Voluntary running in young adult mice reduces anxiety-like behavior and increases the accumulation of bioactive lipids in the cerebral cortex. PLoS One, 8 (12): e81459
76. Schell M J, Brady R O, Molliver M E, Snyder S H (1997). D-serine as a neuromodulator: regional and developmental localizations in rat brain glia resemble NMDA receptors. J Neurosci, 17(5): 1604–1615
77. Schwarcz R, Rassoulpour A, Wu H Q, Medoff D, Tamminga C A, Roberts R C (2001). Increased cortical kynurenate content in schizophrenia. Biol Psychiatry, 50(7): 521–530
78. Sekar A, Bialas A R, de Rivera H, Davis A, Hammond T R, Kamitaki N, Tooley K, Presumey J, Baum M, van Doren V, Genovese G, Rose S A, Handsaker R E, Daly MJ, Carroll MC, Stevens B, McCarroll S A, and the Schizophrenia Working Group of the Psychiatric Genomics Consortium (2016). Schizophrenia risk from complex variation of complement component 4. Nature, 530(7589): 177–183
79. Shimazu T, Hirschey MD, Newman J, He W, Shirakawa K, Le Moan N, Grueter C A, Lim H, Saunders L R, Stevens R D, Newgard C B, Farese R V, de Cabo R, Ulrich S, Akaßsoglou K, Verdin E (2013). Suppression of oxidative stress by ß-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science, 339(6116): 211–214
80. Singer T, McConnell M J, Marchetto M C, Coufal N G, Gage F H (2010). LINE-1 retrotransposons: mediators of somatic variation in neuronal genomes? Trends Neurosci, 33(8): 345–354
81. Smith Q R (2000). Transport of glutamate and other amino acids at the blood-brain barrier. J Nutr, 130(4SSuppl): 1016S–1022S
82. Smoller J W (2016). The genetics of stress-related disorders: PTSD, depression, and anxiety disorders. Neuropsychopharmacology, 41 (1): 297–319
83. Stahl S M, Woo D J, Mefford I N, Berger P A, Ciaranello R D (1983). Hyperserotonemia and platelet serotonin uptake and release in schizophrenia and affective disorders. Am J Psychiatry, 140(1): 26–30
84. Steffens D C, Jiang W, Krishnan K R, Karoly E D, Mitchell M W, O’Connor C M, Kaddurah-Daouk R (2010). Metabolomic differences in heart failure patients with and without major depression. J Geriatr Psychiatry Neurol, 23(2): 138–146
85. Stone JM, Morrison P D, Pilowsky L S (2007). Glutamate and dopamine dysregulation in schizophrenia—a synthesis and selective review. J Psychopharmacol, 21(4): 440–452
86. Stone T W (1993). Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev, 45(3): 309–379
87. Stone W S, Faraone S V, Su J, Tarbox S I, van Eerdewegh P, Tsuang M T (2004). Evidence for linkage between regulatory enzymes in glycolysis and schizophrenia in a multiplex sample. Am J Med Genet B Neuropsychiatr Genet, 127B(1): 5–10
88. Tandon N, Bolo N R, Sanghavi K, Mathew I T, Francis A N, Stanley J A, Keshavan M S (2013). Brain metabolite alterations in young adults at familial high risk for schizophrenia using proton magnetic resonance spectroscopy. Schizophr Res, 148(1-3): 59–66
89. Tortorella A, Monteleone P, Fabrazzo M, Viggiano A, de Luca L, Maj M (2001). Plasma concentrations of amino acids in chronic schizophrenics treated with clozapine. Neuropsychobiology, 44(4): 167–171
90. Upton K r, Gerhardt D J, Jesuadian J S, Richardson S R, Sánchez-Luque F J, Bodea G O, Ewing A D, Salvador-Palomeque C, van der Knaap M S, Brennan P M, Vanderver A, Faulkner G J(2015). Ubiquitous L1 mosaicism in hippocampal neurons. Cell, 161(2): 228–239
91. Vaz A R, Cunha C, Gomes C, Schmucki N, Barbosa M, Brites D (2015). Glycoursodeoxycholic acid reduces matrix metalloproteinase-9 and caspase-9 activation in a cellular model of superoxide dismutase-1 neurodegeneration. Mol Neurobiol, 51(3): 864–877
92. Vingara L K, Yu H J, Wagshul M E, Serafin D, Christodoulou C, Pelczer I, Krupp L B, Maletic-Savatic M (2013). Metabolomic approach to human brain spectroscopy identifies associations between clinical features and the frontal lobe metabolome in multiple sclerosis. Neuroimage, 82: 586–594
93. Wang S M, Han C, Lee S J, Patkar A A, Masand P S, Pae C U (2014). A review of current evidence for acetyl-l-carnitine in the treatment of depression. J Psychiatr Res, 53: 30–37
94. Wang Z J, Li G M, Tang W L, Yin M (2006). Neuroprotective effects of stearic acid against toxicity of oxygen/glucose deprivation or glutamate on rat cortical or hippocampal slices. Acta Pharmacol Sin, 27(2): 145–150
95. Weber H, Klamer D, Freudenberg F, Kittel-Schneider S, Rivero O, Scholz C J, Volkert J, Kopf J, Heupel J, Herterich S, Adolfßson R, Alttoa A, Post A, Grußendorf H, Kramer A, Gessner A, Schmidt B, Hempel S, Jacob C P, Sanjuán J, Moltó MD, Lesch K P, Freitag CM, Kent L, Reif A (2014). The genetic contribution of the NO system at the glutamatergic post-synapse to schizophrenia: further evidence and meta-analysis. Eur Neuropsychopharmacol, 24(1): 65–85
96. Whitfield-Gabrieli S, Thermenos H W, Milanovic S, Tsuang M T, Faraone S V, McCarley R W, Shenton M E, Green A I, Nieto-Castanon A, La Violette P, Wojcik J, Gabrieli J D, Seidman L J (2009). Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia. Proc Natl Acad Sci U S A. 106(4): 1279–1284
97. Wichers M C, Koek G H, Robaeys G, Verkerk R, Scharpé S, Maes M (2005). IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry, 10(6): 538–544
98. Woo H I, Chun M R, Yang J S, Lim SW, Kim M J, Kim SW, Myung W J, Kim D K, Lee S Y (2015). Plasma amino acid profiling in major depressive disorder treated with selective serotonin reuptake inhibitors. CNS Neurosci Ther, 21(5): 417–424
99. Wood P L (2014). Accumulation of N-acylphosphatidylserines and Nacylserines in the frontal cortex in schizophrenia. Neurotransmitter (Houst), 1 (1): e263
100. Wood P L, Holderman N R (2015). Dysfunctional glycosynapses in schizophrenia: disease and regional specificity. Schizophr Res, 166 (1-3): 235–237
101. Wyatt R J, Vaughan T, Galanter M, Kaplan J, Green R (1972). Behavioral changes of chronic schizophrenic patients given L-5- hydroxytryptophan. Science, 177(4054): 1124–1126
102. Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L (2011). Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res, 10(12): 5433–5443
103. Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C (2013). Potential metabolite markers of schizophrenia. Mol Psychiatry, 18(1): 67–78
104. Yanik M, Vural H, Kocyigit A, Tutkun H, Zoroglu S S, Herken H, Savas H A, Köylü A, Akyol O (2003). Is the arginine-nitric oxide pathway involved in the pathogenesis of schizophrenia? Neuropsychobiology, 47(2): 61–65
105. Yao J K, Dougherty G G, Reddy R D, Keshavan M S, Montrose D M, Matson WR, Rozen S, Krishnan R R, McEvoy J, Kaddurah-Daouk R (2010). Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry, 15 (9): 938–953
106. Yao J K, Reddy R (2011). Oxidative stress in schizophrenia: pathogenetic and therapeutic implications. Antioxid Redox Signal, 15(7): 1999–2002
107. Zheng P, Gao H C, Li Q, Shao WH, Zhang M L, Cheng K, Yang Y, Fan S H, Chen L, Fang L, Xie P (2012). Plasma metabonomics as a novel diagnostic approach for major depressive disorder. J Proteome Res, 11(3): 1741–1748
108. Zheng P, Wang Y, Chen L, Yang D, Meng H, Zhou D, Zhong J, Lei Y, Melgiri N D, Xie P (2013). Identification and validation of urinary metabolite biomarkers for major depressive disorder. Mol Cell Proteomics, 12(1): 207–214